The Defender article about 'The Remdesivir Papers':
https://static1.squarespace.com/static/63c72440d8b76f41002cffc6/t/66ff12c8357de971a8a5dcbd/1727992520949/The+Remdesivir+Papers+Final+PDF+Edit.v1-with+endnotes.pdf
"Data derived from the Department of Defense Joint Trauma System (JTS) by a military whistleblower offers a stark contrast to results of multiple clinical trials involving the liberal usage of remdesivir in military treatment facilities and other civilian facilities, as well as its potential contribution to, at minimum, hundreds of untimely deaths.
Interviews with that whistleblower indicate the trials surrounding the use of remdesivir and respective protocols for the treatment of COVID-19 either (1) provided half-truths or (2) kept their secrets close. Big Pharma played their part, and the Department of Defense bought it. Either the U.S. government blindly fell for all of it, considering remdesivir an acceptable treatment for COVID-19 despite a lack of evidence … or it opened itself to investigation."
"A military whistleblower released a series of documents revealing that the military began 'liberally' administering remdesivir to service members who were suspected of having COVID-19 — months before the FDA approved the drug...
According to the whistleblower’s data, 941 military service members died between March 2020 and March 2024. Of those, 63.9%, or 601 service members, were treated with remdesivir...
'While the military is only a subset of the larger population, it’s clear that service members and veterans who contracted severe COVID and were subsequently treated with remdesivir had a much higher chance of dying,' the documents state.
According to the documents, the DOD administered remdesivir to service members — despite the drug’s known risks and dangers...
The drug, developed to treat Ebola, 'was subsequently proven to be lethal in human patients.' According to a 2019 New England Journal of Medicine article, remdesivir resulted in the highest mortality rate among four investigational therapies for Ebola administered in the Democratic Republic of Congo — with 53.1% of patients dying...
Despite its deadly history, in February 2020, Gilead Sciences received FDA approval to initiate two Phase 3 clinical trials to evaluate the efficacy of remdesivir in treating COVID-19.
In March 2020, the DOD announced 'a cooperative research and development agreement with an industry partner' — Gilead — 'to gain access to an antiviral drug for treatment use in our medical centers.'
According to the documents, aside from this expedited approval on the part of the DOD, 'remdesivir moved quickly through government scrutiny,' with the FDA issuing emergency use authorization in August 2020 and full approval in October 2020."
The author holds a Ph.D. in media studies from the University of Texas, 2018, and a master's degree in public policy from Stony Brook University.
© 2016 - 2025 Children's Health Defense® • All Rights Reserved
Children’s Health Defense Re-Publishing Guidelines
https://childrenshealthdefense.org/uncategorized/re-publishing-guidelines/